Pharmasolutions

What Pharmasolutions does

Pharmasolutions is a privately held contract research organization (CRO) headquartered in Cairo, Egypt, founded in 2012 to provide bioequivalence, bioanalytical, and pharmaceutical research services to domestic and international pharmaceutical companies. The company operates from a six-floor, 1,200 m2 facility in New Maadi, Cairo, and is accredited by the Gulf Cooperation Council (GCC) and licensed by the Egyptian Ministry of Health. Its service portfolio is organized around three core lines: bioequivalence studies (full and partial replicate, crossover, parallel, fasting and fed designs conducted under GCP/GLP with bioanalytical methods validated to FDA and EMA guidelines), pharmaceutical analysis (in-vitro comparative dissolution studies for BCS-based biowaivers, plus assay, content uniformity, and dissolution testing under Egyptian MOH supervision), and stability studies (accelerated and long-term per ICH and WHO regulations). The firm also runs a volunteer program to recruit human subjects for clinical studies.

The underlying technology platform is built around conventional, regulated laboratory infrastructure rather than software or AI. The clinical unit occupies roughly 600 m2 and includes a 48-bed accommodation area, an ICU, plasma separation and sample withdrawal areas, controlled -80°C freezers with 24-hour mobile-call alarms, and a fingerprint access-controlled pharmacy. The analytical unit is equipped with LC-MS/MS systems, HPLC, dissolution apparatus, and stability cabinets housed in separate access-controlled labs. Supporting functions include a data management and medical writing unit (pharmacokinetics, statistical calculations, final report writing, and an environmentally controlled archive) and a quality assurance unit that verifies all clinical, bioanalytical, pharmacokinetics, statistical, and reporting activities for GLP and ICH/GCP compliance. The firm states it has developed 100+ validated bioanalytical methods across pharmaceutical compounds.

Pharmasolutions generates revenue on a professional-services, contract basis by selling study execution and analysis to pharmaceutical sponsors requiring bioequivalence, pharmaceutical analysis, and stability data for generic-drug regulatory submissions. Pricing is quote-based and not publicly disclosed, consistent with CRO industry norms. The go-to-market is direct engagement with pharmaceutical sponsors, supported by a corporate website and basic social media presence. Geographic scope is positioned as Middle East and Africa, anchored by Egyptian operations and GCC accreditation. Ownership appears concentrated with the co-founder (Ehab Farouk Elkady) and listed staff; no institutional investors, parent company, subsidiaries, M&A, or external funding rounds are disclosed in the available materials.

Name

Pharmasolutions

Legal name

Pharmasolutions

Website

https://pharmasolutions-egypt.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharmasolutions is a privately held Cairo-based contract research organization founded in 2012 that provides bioequivalence, bioanalytical, and pharmaceutical research services to domestic and international pharmaceutical sponsors across the Middle East and Africa region, operating from a 1,200 m2 facility.

Ownership category

akta.pro rank

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: Pharmasolutions generates revenue by providing bioequivalence, bioanalytical, and pharmaceutical research services to domestic and international pharmaceutical companies on a contract basis

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Pharmasolutions is a contract research organization that conducts bioequivalence studies (full and partial replicate, crossover and parallel, fasting and fed), pharmaceutical analysis (comparative in-vitro dissolution studies), and stability studies (accelerated and long-term) for domestic and international pharmaceutical companies. The work is delivered through a Cairo-based facility with a 48-bed clinical unit, LC-MS/MS analytical laboratories, data management/medical writing, and an in-house quality assurance unit operating under GCP and GLP standards.

Product overview

Pharmasolutions is a privately owned Contract Research Organization (CRO) established in 2012, offering a unified portfolio of bioequivalence, bioanalytical, and pharmaceutical research services to domestic and international pharmaceutical companies. The core offering comprises three main service lines: Bioequivalence Studies (full/partial replicate studies, crossover/parallel studies, fasting/fed studies), Pharmaceutical Analysis (in-vitro lab with comparative dissolution studies), and Stability Studies (accelerated and long-term studies per ICH/WHO guidelines). These services are supported by four operational facilities: Clinical Unit (600 m2 with 48-bed accommodation, pharmacy, ICU), Analytical Unit (LC-MC/MS systems, HPLC, dissolution apparatus), Data Management and Medical Writing Unit, and Quality Assurance Unit. All studies are conducted under GCP/GLP standards, accredited by GCC, and licensed by Egyptian Ministry of Health.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioequivalence Studies Full and partial replicate bioequivalence studies, crossover and parallel studies, and fasting and fed studies conducted per ethical committee-approved protocols, SOPs, current GCP and GLP standards, and applicable regulatory requirements; includes bioanalytical method development and validation in accordance with FDA and EMA guidelines for pharmaceutical sponsors requiring therapeutic equivalence data.
• Pharmaceutical Analysis In-vitro pharmaceutical analysis service from a fully equipped laboratory, including comparative dissolution studies per international guidelines for biowaiver of bioequivalence studies based on BCS or dose proportionality, plus assay, uniformity of dosage forms, and dissolution under Egyptian Ministry of Health supervision, for pharmaceutical companies and generic sponsors.
• Stability Studies Accelerated and long-term stability studies for different dosage forms, complying with the latest ICH and WHO regulations, provided to pharmaceutical companies for regulatory submission packages.

Quantifiable outcome

• 100+ validated bioanalytical methods for various pharmaceutical compounds

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Parexel International: Global CRO providing clinical research, bioanalytical, and regulatory services. Comparable as a broad incumbent whose portfolio overlaps with Pharmasolutions' BE and bioanalytical offerings.
• Syneos Health: Global biopharmaceutical solutions organization offering clinical development and bioanalytical services. Broad incumbent competing in the same sponsor universe for outsourced pharmaceutical research.
• Charles River Laboratories: Global CRO with established bioanalytical, safety assessment, and manufacturing services. Broad incumbent offering overlapping bioanalytical and BE capabilities as part of a much wider life-sciences services portfolio.
• IQVIA: World's largest CRO with full clinical, bioanalytical, and real-world evidence services. Broad incumbent operating across the entire clinical development value chain, including bioequivalence work.
• ICON plc: Global CRO with clinical, bioanalytical, and laboratory services for pharma and biotech. Comparable as a full-service CRO that includes BE/bioanalytical work in a broader portfolio.

Direct peers

• Frontage Laboratories: US-headquartered CRO with bioanalytical services and bioequivalence capabilities serving pharmaceutical sponsors globally. Highly comparable business model — contract bioanalytical and BE services — though at materially larger scale.
• Lotus Clinical Research: Bioequivalence and clinical research CRO operating in emerging markets. Directly comparable in bioequivalence-focused CRO service mix targeting generic pharmaceutical sponsors.
• Cliantha Research: India-based clinical research and bioequivalence CRO providing bioanalytical, clinical, and dermatology services. Comparable as a regionally-headquartered bioequivalence CRO serving global pharma sponsors.
• Lambda Therapeutics: India-based CRO offering bioequivalence and bioanalytical services to pharmaceutical sponsors. Directly comparable in service mix, target customer (generic pharma), and cost-arbitrage positioning versus Western CROs.
• Accutest Research Labs: India-based bioanalytical CRO offering method development, validation, and clinical sample analysis. Comparable as a bioanalytical-focused CRO serving generic and innovator pharma.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/pharmasolutionscro
• LinkedInlinkedin.com/company/pharmasolutions-cro

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmasolutions